Background: HER2-positive breast cancers are rare amongst BRCA mutation carriers. No data exist regarding clinicopathological characteristics and prognosis of this subgroup of patients. Materials and methods: Using a retrospective matched cohort design, we collected data from 700 women who were diagnosed with operable invasive breast cancer from January 2006 to December 2016 and were screened for germline BRCA mutations. Clinicopathological features and survival rates were analyzed by BRCA and HER2 status. Results: One hundred and fifteen HER2-positive/BRCA mutated cases were evaluated in comparison to the three control groups: HER2-positive/BRCA wild type (n = 129), HER2-negative/BRCA mutated (n = 222), HER2-negative/BRCA wild type (n = 234). HER2-positive breast cancers were more likely to have high histologic grade and high proliferation rate than HER2-negative neoplasms, regardless of BRCA mutation status. An interaction between BRCA mutations and HER2-positive status was found to correlate with worse survival after adjusting for prognostic variables (HR = 3.4; 95% CI: 1.3-16.7). Conclusions: Co-occurrence of BRCA mutations and HER2-positive status is a poor prognostic factor in patients with early or locally advanced breast cancer. This finding may be a proof of concept that a combined pharmacological intervention directed to these targets could be synergistic.

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer / Viansone, A; Pellegrino, B; Omarini, C; Pistelli, M; Boggiani, D; Sikokis, A; Uliana, V; Zanoni, D; Tommasi, C; Bortesi, B; Bonatti, F; Piacentini, F; Cortesi, L; Camisa, R; Sgargi, P; Michiara, M; Musolino, A.. - In: BREAST. - ISSN 1532-3080. - 65:(2022), pp. 145-150. [10.1016/j.breast.2022.07.012]

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.

Omarini C;Piacentini F;
2022-01-01

Abstract

Background: HER2-positive breast cancers are rare amongst BRCA mutation carriers. No data exist regarding clinicopathological characteristics and prognosis of this subgroup of patients. Materials and methods: Using a retrospective matched cohort design, we collected data from 700 women who were diagnosed with operable invasive breast cancer from January 2006 to December 2016 and were screened for germline BRCA mutations. Clinicopathological features and survival rates were analyzed by BRCA and HER2 status. Results: One hundred and fifteen HER2-positive/BRCA mutated cases were evaluated in comparison to the three control groups: HER2-positive/BRCA wild type (n = 129), HER2-negative/BRCA mutated (n = 222), HER2-negative/BRCA wild type (n = 234). HER2-positive breast cancers were more likely to have high histologic grade and high proliferation rate than HER2-negative neoplasms, regardless of BRCA mutation status. An interaction between BRCA mutations and HER2-positive status was found to correlate with worse survival after adjusting for prognostic variables (HR = 3.4; 95% CI: 1.3-16.7). Conclusions: Co-occurrence of BRCA mutations and HER2-positive status is a poor prognostic factor in patients with early or locally advanced breast cancer. This finding may be a proof of concept that a combined pharmacological intervention directed to these targets could be synergistic.
31-lug-2022
65
145
150
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer / Viansone, A; Pellegrino, B; Omarini, C; Pistelli, M; Boggiani, D; Sikokis, A; Uliana, V; Zanoni, D; Tommasi, C; Bortesi, B; Bonatti, F; Piacentini, F; Cortesi, L; Camisa, R; Sgargi, P; Michiara, M; Musolino, A.. - In: BREAST. - ISSN 1532-3080. - 65:(2022), pp. 145-150. [10.1016/j.breast.2022.07.012]
Viansone, A; Pellegrino, B; Omarini, C; Pistelli, M; Boggiani, D; Sikokis, A; Uliana, V; Zanoni, D; Tommasi, C; Bortesi, B; Bonatti, F; Piacentini, F; Cortesi, L; Camisa, R; Sgargi, P; Michiara, M; Musolino, A.
File in questo prodotto:
File Dimensione Formato  
BRCA HER2pos.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 614.53 kB
Formato Adobe PDF
614.53 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1285650
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact